Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
SEC Accession No. 0001193125-25-024783
Filing Date
2025-02-12
Accepted
2025-02-12 07:50:10
Documents
1
Effectiveness Date
2025-02-12

Document Format Files

Seq Description Document Type Size
1 POSASR d887700dposasr.htm POSASR 19891
  Complete submission text file 0001193125-25-024783.txt   20967
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: POSASR | Act: 33 | File No.: 333-275548 | Film No.: 25612014
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)